Neoantigen Targeted Therapies Market - Global Forecast 2025-2032

Neoantigen targeted therapies are rapidly advancing the landscape of personalized oncology. Senior executives need a clear, data-driven understanding of this evolving market to guide investments, strategies, and operations in immunotherapeutic innovation.

Market Snapshot: Neoantigen Targeted Therapies Market

The Neoantigen Targeted Therapies Market was valued at USD 4.57 billion in 2024 and is projected to reach USD 5.30 billion in 2025, reflecting a compound annual growth rate (CAGR) of 16.57%. By 2032, the market is expected to achieve USD 15.61 billion, driven by accelerating clinical advancements, the expansion of therapeutic indications in oncology, and increased participation from healthcare players. Innovative genomics and the rise of data-supported evidence are propelling the adoption of these cutting-edge immunotherapeutic approaches within major oncology settings.

Scope & Segmentation: Comprehensive Analysis of Neoantigen Targeted Therapies

The report delivers detailed segmentation to support strategic decisions and resource prioritization by senior leaders across the oncology ecosystem. It covers trends, platforms, and stakeholders vital to the current and emerging market.

• Therapy Modality: Encompasses Adoptive Cell Therapy, such as CAR-T, T Cell Receptor, and Tumor-infiltrating Lymphocytes, alongside Personalized Neoantigen Vaccines including Dendritic Cell, DNA/RNA-based, and Peptide types.
• Treatment Approach: Evaluates Combination Therapy and Monotherapy, adaptable to a wide variety of disease states and tailored patient needs.
• Route of Administration: Includes both Oral and Parenteral options, covering Intramuscular, Intravenous, and Subcutaneous pathways to align with diverse clinical protocols.
• Age Group: Analyzes demand across Adult, Geriatric, and Pediatric populations, highlighting cross-generational oncology trends and prevalence variations.
• Target Disease Indication: Covers Bone, Colorectal, Gynecological, Non-Small Cell Lung, and Renal Cell Carcinoma, reflecting the burden and strategic focus areas in oncology care.
• End-User: Reviews the roles of Academic & Government Research Institutes, Hospitals & Clinics, and Specialty Clinics in championing adoption and driving utilization.
• Region: Provides market breakdowns by Americas (including North America and Latin America), Europe, Middle East & Africa (offering specific country insights), and Asia-Pacific divisions for a granular regional strategic framework.
• Key Players: Profiles principal organizations such as Achilles Therapeutics Limited, Agenus Inc., AstraZeneca plc, BioNTech SE, Bristol-Myers Squibb Company, CureVac N.V., Eli Lilly and Company, EpiVax, Inc., F. Hoffmann-La Roche AG, Genentech, Inc., Genocea Biosciences, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Gritstone bio, Inc., Immatics N.V., Immunomic Therapeutics, Inc., IOVANCE Biotherapeutics, Inc., Medigene AG, Merck & Co., Inc., Moderna, Inc., Neon Therapeutics, Inc., Nykode Therapeutics, Pfizer Inc., Precision Biologics, and Valo Therapeutics Ltd.

Key Takeaways: Actionable Insights for Senior Decision-Makers

• The fusion of genomics, immunology, and bioengineering is steering the next phase of personalized therapeutics in oncology.
• Advances in high-throughput sequencing and bioinformatics enhance identification of targetable neoantigens, increasing the pipeline of novel therapies.
• Adaptive regulatory frameworks and clinical trial models are fostering streamlined approvals, promoting market entry of new immunotherapies.
• Collaboration among biopharma companies, research institutes, and manufacturers is optimizing R&D efficiency and enabling scalability in clinical rollouts.
• Distinct competitive advantages are evident regionally, with the Americas leading in research investment, EMEA refining reimbursement models, and Asia-Pacific delivering robust manufacturing capacity.
• Artificial intelligence is playing a collaborative role in guiding rapid drug discovery, optimizing strategic partnerships, and safeguarding intellectual property in a competitive market landscape.

Tariff Impact: Navigating Supply Chain and Cost Pressures

Recent U.S. tariff changes have elevated input costs for essential reagents and equipment integral to neoantigen therapy production and distribution. In response, many organizations are diversifying their supplier base, encouraging local manufacturing growth, and investing in digital supply chain management tools. Proactive scenario planning is recommended to help organizations sustain stable clinical and commercial operations and address logistical uncertainties.

Methodology & Data Sources

The report combines primary insights from expert interviews with secondary research from peer-reviewed journals, regulatory publications, and proprietary databases. This triangulated methodological approach ensures validation and depth, supporting confident executive strategies across all market segments.

Why This Report Matters

• Empowers senior executives to make data-informed decisions on partnerships, investment, and commercialization in neoantigen targeted strategies.
• Offers a structured perspective on segmentation, latest technological progress, and regional market shifts to support effective go-to-market approaches.
• Equips organizations to anticipate regulatory change and manage supply chain challenges, helping to maximize operational and commercial outcomes.

Conclusion

Neoantigen targeted therapies are redefining how oncology care is delivered. With comprehensive market intelligence, senior leaders can confidently identify new opportunities, enhance value, and secure sustainable growth trajectories.

 

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.